Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia.

Justin LokeMyriam LabopinCharles CraddockJan J CornelissenHélène Labussière-WalletEva Maria Wagner-DrouetGwendolyn Van GorkomNicolaas P M SchaapNicolaus M KrögerJoan Hendrik VeelkenMontserrat RoviraAnne Lise MenardGesine BugAli BazarbachiSebastian GiebelEolia BrissotArnon NaglerJordi EsteveMohamad Mohty

Published in: Cancer (2022)

In summary, the adverse prognostic effect of TP53 mutations in AML following an allo-SCT is not evident in patients with neither co-occurring 17p- and/or CK, and these data inform decisions regarding allo-SCT in patients with TP53 mutant AML.

Keyphrases

acute myeloid leukemia
end stage renal disease
allogeneic hematopoietic stem cell transplantation
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
emergency department
wild type
patient reported outcomes
big data
adverse drug